NCT01999764

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: QLT Inc. · Industry
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase IIa proof-of-concept study to evaluate the effects of oral QLT091001 on adults with impaired dark adaptation.

Detailed description

This proof-of-concept study is a randomized, parallel design of two different oral doses of QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark adaptation. Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the US.

Conditions

• Impaired Dark Adaptation

Interventions

Type	Name	Description
DRUG	QLT091001	QLT091001 administered orally at multiple time points.
OTHER	Placebo	Placebo is administered orally at multiple time points.

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-06-01
• Completion: 2014-07-01
• First posted: 2013-12-03
• Last updated: 2015-07-14

Locations

7 sites across 1 country: United States